Product Overview
Canine IL-13 R alpha 2, His Tag is expressed from HEK293. It contains AA Ser 22 - Thr 338.
Predicted N terminal
Ser 22
Molecular Weight
The protein has a calculated MW of 40.3 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Bio-activity
Immobilized Canine IL-13 R alpha 2, His Tag at 1 μg/mL can bind Monoclonal Anti-IL-13 R alpha 2 Antibody. EC50=1.83 ng/mL.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Alternative Names
IL13RA2; CD213A2; CT19; IL-13R; IL13BP
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Buffer
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
This product is stable after storage at: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
Introduction
Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) is a high-affinity receptor for interleukin-13 (IL-13), a cytokine involved in immune regulation, inflammation, and tumor biology. Unlike IL-13Rα1, which forms a signaling receptor complex with IL-4Rα, IL-13Rα2 lacks a functional intracellular signaling domain and primarily acts as a decoy receptor, regulating IL-13 availability and signaling intensity. IL-13Rα2 is expressed in various tissues, including the lungs, liver, and reproductive organs, and is notably overexpressed in several types of cancers such as glioblastoma, pancreatic, and colorectal carcinomas. Due to its restricted expression in normal tissues and high expression in tumors, IL-13Rα2 has become an attractive target for cancer immunotherapy and diagnostic applications.
Keywords
IL13RA2; CD213A2; CT19; IL-13R; IL13BP
Citations
Publication ()
Have you cited DAGC-55276 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
